Agenus (NASDAQ:AGEN – Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, March 14th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
Agenus Price Performance
NASDAQ:AGEN opened at $0.67 on Tuesday. The firm’s 50 day simple moving average is $0.69 and its 200 day simple moving average is $0.86. Agenus has a one year low of $0.53 and a one year high of $2.13. The company has a market cap of $268.85 million, a PE ratio of -0.82 and a beta of 1.28.
Insider Activity at Agenus
In other news, insider Garo H. Armen purchased 500,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were acquired at an average price of $0.65 per share, with a total value of $325,000.00. Following the transaction, the insider now owns 625,969 shares of the company’s stock, valued at $406,879.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Agenus
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Friday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Agenus presently has a consensus rating of “Moderate Buy” and an average target price of $8.10.
Get Our Latest Stock Analysis on AGEN
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
- Five stocks we like better than Agenus
- 3 Tickers Leading a Meme Stock Revival
- Unbearably Good Investment: A Build-A-Bear Stock Analysis
- Trading Stocks: RSI and Why it’s Useful
- Coinbase Stock Tempting but isn’t without its Risks
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- This Industrial Products Stock is Goldman’s Favorite This Cycle
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.